Latest Views & analysis
Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
What will Macron’s government mean for healthcare in his country and Europe?
More Views & Analysis
AI can sift and analyse vast amounts of genomic data, enabling clinical scientists to better diagnose patients.
Investors who see early-stage compounds and indications as valuable assets can support them to market.
Apple becomes first ‘big tech’ firm to investigate sleep technology.
The new head of Novartis UK thinks the country has gone backwards in terms of access to medicines.
Industry may be limiting its options if safety takes a back seat to efficacy in trial design and product development.